LINC01001: A Drug Target / Disease Biomarker (G100133161)

Target Name: LINC01001

NCBI ID: G100133161

LINC01001

Other Name(s): Long intergenic non-protein coding RNA 1001, transcript variant 2 | long intergenic non-protein coding RNA 1001

LINC01001: A Drug Target / Disease Biomarker

LINC01001 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell's DNA replication process, which is a critical process for the development and maintenance of the cell. LINC01001 has been shown to play a role in the regulation of gene expression, and it has been linked to a number of diseases, including cancer.

The discovery and characterization of LINC01001 began in the late 1990s, when researchers identified a highly conserved RNA molecule that was highly expressed in a variety of tissues and cells. The RNA molecule was later shown to have a role in the regulation of gene expression, and it was renamed LINC01001.

Since its discovery, LINC01001 has been extensively studied to better understand its functions and potential as a drug target. One of the key findings of these studies is that LINC01001 plays a critical role in the regulation of DNA replication.

During DNA replication, LINC01001 is involved in the creation of a double helix that contains the genetic information from one strand of DNA to the other. It is one of several proteins that work together to ensure the accuracy and efficiency of DNA replication.

In addition to its role in DNA replication, LINC01001 has also been shown to play a critical role in the regulation of gene expression. It has been shown to interact with a variety of transcription factors, which are proteins that help to turn on or off the genes that are expressed in the cell.

LINC01001 has also been linked to a number of diseases, including cancer. For example, studies have shown that LINC01001 is often expressed at higher levels in cancer cells than in normal cells. This suggests that it may be a useful biomarker for the diagnosis and treatment of cancer.

In addition to its potential as a drug target and biomarker, LINC01001 is also of interest to researchers because of its unique structure and biology. Unlike many proteins, LINC01001 is not a typical RNA molecule. It is a non-coding RNA molecule, which means that it does not have a defined sequence of amino acids. Instead, it consists of a series of RNA loops that are held together by a protein called TAP, which is also a key regulator of LINC01001's function.

The study of LINC01001 has also highlighted the importance of the cell's DNA replication process in the development and maintenance of the cell. Many diseases, including cancer, are caused by disruptions in the cell's DNA replication process. By understanding how LINC01001 functions in this process, researchers may be able to develop new treatments for these diseases.

In conclusion, LINC01001 is a non-coding RNA molecule that has been shown to play a critical role in the regulation of the cell's DNA replication process. Its potential as a drug target and biomarker makes it an attractive target for further research. Understanding how LINC01001 functions in the cell's DNA replication process may also reveal new insights into the development and maintenance of the cell.

Protein Name: Long Intergenic Non-protein Coding RNA 1001

The "LINC01001 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01001 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets